DermTech, Inc. announced agreements with a Blues plan in South Carolina and the United Mine Workers of America Health and Retirement Funds. The contracts, which are both effective April 1, 2023, enhance access to the foundational assay of the DermTech Melanoma Test (“DMT”) for the approximately 1.7 million members of the Blues plan in South Carolina and the 90,000 beneficiaries of the UMWA Funds. The UMWA Funds is a group of multi-employer plans that provide health and pension benefits to retired coal miners and their eligible dependents.

The DMT is an innovative, non-invasive way to enhance melanoma detection with a greater than 99% negative predictive value (“NPV”). DermTech's total covered lives in the U.S. are approximately 126 million, which includes 68 million for Medicare/Medicare Advantage and 58 million for commercial and governmental payers.